Latest filing published 08 Jul 2015 for Galectin Therapeutics INC.
Insider track record
No signal scores available.
Closed purchases
Based on 12 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -59.5%Entry US$8.32 · Close at T+365 US$3.37
- -58.1%Entry US$9.24 · Close at T+365 US$3.87
- -41.4%Entry US$8.52 · Close at T+365 US$4.99
- -60.6%Entry US$12.06 · Close at T+365 US$4.75
- -21.8%Entry US$7.43 · Close at T+365 US$5.81
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
John F. Mauldin: trading record in brief
John F. Mauldin discloses dealings in Galectin Therapeutics Inc to SEC (Form 4). Over a trading history stretching from 24 April 2012 to 8 April 2015, the count stands at 14 filings.
Every open-market trade on record is a purchase: 12 purchases worth €41k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 2 share grants.
Half of the purchases are above €3,634 and half below. Looking at 12 purchases old enough to measure, the stock rose over the following 90 days in 67% of cases; the median change was +46.6%. They describe history only and say nothing certain about the share price ahead.
On 8 July 2015 came the latest disclosure, a share grant in Galectin Therapeutics Inc. The latest purchase dates back some time: it was published 4,694 days ago, on 2 January 2014. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to John F. Mauldin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 11,112 shares0Common StockSEC:0001179022-15-000082:0
- 25,483 shares0Common StockSEC:0001179022-15-000082:1
- 618 shares@ US$8.01Common StockSEC:0000914062-14-000002:0Canonical exit: 2 Apr 2014 (T+90)
- 609 shares@ US$8.20Common StockSEC:0000914062-13-000365:0Canonical exit: 2 Mar 2014 (T+90)
- 478 shares@ US$10.43Common StockSEC:0000914062-13-000255:0Canonical exit: 30 Jan 2014 (T+90)
- 376 shares@ US$9.96Common StockSEC:0000914062-13-000232:0Canonical exit: 30 Dec 2013 (T+90)
- 125 shares@ US$9.97Common StockSEC:0000914062-13-000232:1Canonical exit: 31 Dec 2013 (T+90)
- 676 shares@ US$7.38Common StockSEC:0000914062-13-000230:0Canonical exit: 3 Dec 2013 (T+90)
- 840 shares@ US$5.94Common StockSEC:0000914062-13-000218:0Canonical exit: 3 Nov 2013 (T+90)
- 876 shares@ US$4.23Common StockSEC:0000914062-13-000211:0Canonical exit: 1 Oct 2013 (T+90)
- 300 shares@ US$4.24Common StockSEC:0000914062-13-000209:0Canonical exit: 29 Sept 2013 (T+90)
- 1,176 shares@ US$4.21Common StockSEC:0000914062-13-000197:0Canonical exit: 1 Sept 2013 (T+90)
- 3,847 shares@ US$2.94Common StockSEC:0001181431-12-025889:0Canonical exit: 23 Jul 2012 (T+90)
- 1,100 shares@ US$3.08Common StockSEC:0001181431-12-025889:1Canonical exit: 24 Jul 2012 (T+90)
14 of 14 declarations
